Partnering ‘on tap’ for Munich in 2010
Horst Domdey is looking forward to welcoming BIO-Europe back to Munich.
“We were just a baby biocluster, not even a cluster really, when this event was last held in Munich in 2001,” said Domdey, the head of BioM Biotech Cluster Development.
“It has been a busy time for us, launching successful companies, drugs that have been approved as well as new development programs,” he said.
“It is going to be a pleasure to host EBD Group’s community of business development executives,” he said, “we have quite an impressive community ourselves and many opportunities to present.”
The Munich life science industry today is made up of 43 pharmaceutical companies and 136 biotechnology companies, eight of which have successfully been listed as public companies.
Among the biotechs, 118 are SMEs employing 2,600 employees of which 60 percent are dedicated to development projects for therapeutics and diagnostic agents.
“Our focus is drug development,” said Domdey, “this is where we have scored points quickly and have developed as a major player.”
“There is a very good story here for people interested in targeted therapies as we have a number of companies working in that area and several university-based projects,” he said.
BioM Biotech Cluster is also the coordinating agency for the state of Bavaria, collecting another 14 local programs.
“We did not have much presence the first time BIO-Europe visited Munich, but now we have a critical mass that should be quite impressive,” said Domdey.
Related Posts
No related posts.